{
  "component_scores": {
    "joint_involvement": {
      "score": 5,
      "justification": "Multiple mentions of polyarthrite rhumatoïde and arthrite rhumatoïde indicate significant joint involvement."
    },
    "serology": {
      "score": 0,
      "justification": "No laboratory results provided, specifically RF or anti-CCP levels."
    },
    "acute_phase": {
      "score": 0,
      "justification": "Laboratory results are not available for CRP or ESR."
    },
    "duration": {
      "score": 1,
      "justification": "Biologic DMARDs (adalimumab) indicate chronic/long-standing disease, suggesting established RA."
    }
  },
  "acr_eular_total": 6,
  "treatment_context": {
    "has_dmard": true,
    "treatment_strength": "strong",
    "justification": "The patient is on methotrexate (csDMARD) and adalimumab (bDMARD), which provides strong evidence for established RA."
  },
  "final_label": "RA+",
  "classification_rationale": "The patient has a high score in joint involvement with multiple mentions of polyarthrite rhumatoïde, clear clinical picture supported by biologic DMARDs, and chronic/long-standing disease evidenced by the use of adalimumab. Treatment strength is considered strong due to the combination of methotrexate and adalimumab.",
  "confidence": "high",
  "patient_id": "0001",
  "agent": "Agent2_LLM_Reasoning_BALANCED",
  "retrieved_guidelines": [
    {
      "title": "Clinical Context",
      "content": "Treatment patterns provide additional evidence:\n- Methotrexate (MTX) = first-line csDMARD\n- Biologic DMARDs (anti-TNF, anti-IL6, etc.) = established RA\n- JAK inhibitors = treatment-refractory RA\n\nIn clinical practice:\n- Score ≥6/10 = definite RA\n- Score 4-5/10 + DMARD treatment = probable established RA\n- Score ≥5/10 without treatment = borderline, likely RA",
      "text": "Clinical Context Treatment patterns provide additional evidence:\n- Methotrexate (MTX) = first-line csDMARD\n- Biologic DMARDs (anti-TNF, anti-IL6, etc.) = established RA\n- JAK inhibitors = treatment-refractory RA\n\nIn clinical practice:\n- Score ≥6/10 = definite RA\n- Score 4-5/10 + DMARD treatment = probable established RA\n- Score ≥5/10 without treatment = borderline, likely RA",
      "relevance_score": 4.683000883810066
    },
    {
      "title": "Category A: Joint Involvement (0-5 points)",
      "content": "- 1 large joint: 0 points\n- 2-10 large joints: 1 point\n- 1-3 small joints (with or without large joints): 2 points\n- 4-10 small joints (with or without large joints): 3 points\n- >10 joints (at least 1 small joint): 5 points\n\nLarge joints: shoulders, elbows, hips, knees, ankles\nSmall joints: MCPs, PIPs, MTPs (2nd-5th), thumb IPs, wrists",
      "text": "Category A: Joint Involvement (0-5 points) - 1 large joint: 0 points\n- 2-10 large joints: 1 point\n- 1-3 small joints (with or without large joints): 2 points\n- 4-10 small joints (with or without large joints): 3 points\n- >10 joints (at least 1 small joint): 5 points\n\nLarge joints: shoulders, elbows, hips, knees, ankles\nSmall joints: MCPs, PIPs, MTPs (2nd-5th), thumb IPs, wrists",
      "relevance_score": 2.188326647736484
    },
    {
      "title": "Classification Criteria (Score-based algorithm)",
      "content": "A score of ≥6/10 is needed for classification as definite RA.",
      "text": "Classification Criteria (Score-based algorithm) A score of ≥6/10 is needed for classification as definite RA.",
      "relevance_score": 0.7797536738596373
    }
  ],
  "guideline_citation": "Aletaha D, et al. Arthritis Rheum. 2010;62(9):2569-2581",
  "evidence_trace": [
    {
      "type": "disease_mention",
      "stay_id": "S0001",
      "line_no": 0,
      "snippet": "Patient masculin de 58 ans, retraité, consulte pour douleurs diffuses aux membres inférieurs depuis "
    },
    {
      "type": "disease_mention",
      "stay_id": "S0001",
      "line_no": 0,
      "snippet": "Patient masculin de 58 ans, retraité, consulte pour douleurs diffuses aux membres inférieurs depuis "
    },
    {
      "type": "disease_mention",
      "stay_id": "S0001",
      "line_no": 6,
      "snippet": "Diagnostic évoqué : polyarthrite rhumatoïde probable, mais sérologies négatives."
    },
    {
      "type": "disease_mention",
      "stay_id": "S0001",
      "line_no": 6,
      "snippet": "Diagnostic évoqué : polyarthrite rhumatoïde probable, mais sérologies négatives."
    },
    {
      "type": "disease_mention",
      "stay_id": "S0002",
      "line_no": 0,
      "snippet": "Hospitalisation pour douleurs abdominales diffuses, fièvre à 38,4°C, asthénie. Évolution depuis 2 se"
    },
    {
      "type": "disease_mention",
      "stay_id": "S0002",
      "line_no": 0,
      "snippet": "Hospitalisation pour douleurs abdominales diffuses, fièvre à 38,4°C, asthénie. Évolution depuis 2 se"
    },
    {
      "type": "drug",
      "name": "methotrexate",
      "stay_id": "S0001",
      "line_no": 7,
      "snippet": "Prise en charge : début de méthotrexate 15 mg/semaine per os, avec acide folique 5 mg/j."
    },
    {
      "type": "drug",
      "name": "adalimumab",
      "stay_id": "S0002",
      "line_no": 0,
      "snippet": "Hospitalisation pour douleurs abdominales diffuses, fièvre à 38,4°C, asthénie. Évolution depuis 2 se"
    },
    {
      "type": "drug",
      "name": "adalimumab",
      "stay_id": "S0002",
      "line_no": 6,
      "snippet": "Prise en charge : antibiotiques (métronidazole + ceftriaxone), arrêt définitif de l’adalimumab."
    }
  ]
}